Arterra Bioscience Spa · MIL:ARBS
Arterra Bioscience Spa — Investor Conference Naples (Banca Profilo) 2026
31 slides from Arterra Bioscience Spa's conference presentation, Oct 5, 2026
Slide 1: 20+ years of innovation and research in nature-inspired bioactives
INVESTOR CONFERENCE NAPLES Banca Profilo 20+ years of innovation and research in nature-inspired bioactives for industrial application OCTOBER 5th, 2026
Slide 2: People Speaking Today
PEOPLE SPEAKING TODAY M. GABRIELLA COLUCCI Founder, President and CEO GUALTIERO IOIMO CFO and Investor Relations Manager
Slide 3: Arterra Bioscience - Innovative SME
ARTERRA BIOSCIENCE - Innovative SME Arterra Bioscience is a biotech company listed on the “Euronext Growth Milan” market of Borsa Italiana since 2019, founded in Naples by M. Gabriella Colucci in 2004 with the aim of developing technologies and innovative solutions that find application in various i
Slide 4: Who holds the pulse of innovation
who holds the pulse of innovation
Slide 5: Arterra & Vitalab Team
ARTERRA & VITALAB TEAM PhD 16 2 PhD Chem Ing 9 MSc 1,600 m² 33 12 11 7 2 Tech Administration PhD Students LABORATORIES PEOPLE
Slide 6: Management Team
MANAGEMENT TEAM M. GABRIELLA COLUCCI GUALTIERO IOIMO VINCENZO FOGLIANO CEO CFO CSO GIUSEPPE FERRANTE MARIDA BIMONTE ANNALISA TITO COO Grant & IP Director Cell & Mol Biol. Director
Slide 7: Company Organization
COMPANY ORGANIZATION PRESIDENT & CEO Gabriella ACCOUNTING FINANCIAL MANAGEMENT ASSISTANT / INVESTOR RELATIONS Gualtiero Alexandra QUALITY CONTROL SCIENTIFIC COORDINATOR Luigi Vincenzo VITALAB MARKETING AND REGULATORY BUSINESS DEVELOPER Claudia, Natascia & Francesca Alessandro PRODUCTION DIRECTOR GRA
Slide 8: From the Idea to the Product
FROM THE IDEA TO THE PRODUCT Microbiology / Chemistry / Scientific Breakthrough / Biochemistry Genetic Engineering / Plants / New Tech. / Skin Biology 01 THINK TANK TEAM TTU Insight and Feasibility of Ideas Think Tank Research Units Management Team Approval 02 INNOVATION TEAM IU From Idea to Prototy
Slide 9: Innovation & Production Capabilities
INNOVATION & PRODUCTION CAPABILITIES More than 50 71 Global R&D Partners Scientific Publications State-of-art 25 Patents 7 Lab Facility 1600 sqm Innovation Awards Tons of product 15 produced in 2025 ISO 9001:2015 ISO 14001:2015 ISO 45001:2018 RSPO Supply Chain Certification Standard Climate Partner
Slide 10: Awakening Beauty. Globally
60 AWAKENING BEAUTY. GLOBALLY Million 50ml SKUs formulated with Vitalab Actives in 2025* *calculated by multiplying 2025 Total Sales (Volume) per avg. recommended dose divided SKU size (50 ml)
Slide 11: Funded Projects
FUNDED PROJECTS Re-Food SmartLab 2.0 Main Cosmetic NEX-Bio Regional Programme FUNDING / Regional funding MIMIT MUR 2026-2029 STEP BIS Call PERIOD 2024–2026 2027–2029 2027–2028 Next-generation RESEARCH Agrifood and circular Microbiological Cell Innovative materials bioactive ingredients AREA economy
Slide 12: 2026: A Year of Transition
2026: A YEAR OF TRANSITION COSMETICS NUTRACEUTICALS Closer to dermatology A strong discovery platform Beauty brands are increasingly aligned with A solid scientific foundation for developing dermatology and aesthetic medicine. nutraceutical ingredients and novel food ingredients. Makeup with skincar
Slide 13: The New Vitalab Team
THE NEW VITALAB TEAM Building brand awareness and competitiveness Our focus is to build a modern, consistent and distinctive brand identity that reflects: WHO WE ARE WHAT WE STAND FOR THE VALUE WE BRING TO OUR CUSTOMERS Natascia / Claudia / Francesca
Slide 14: From Vita on Earth, for Vita on Earth
At our core Vita One Source, One Target From Vita on Earth, for Vita on Earth.
Slide 15: Introducing Glowing Skin Quality Matrix
X-INDUSTRY WITH DERMATOLOGY & AESTHETIC MEDICINE Introducing Glowing Skin Quality Matrix HYDRATION RADIANCE Multidimensional framework to SKIN COMFORT HYPERPIGMENTATION assess the overall health, PLUMPING functionality & appearance BARRIER FUNCTION of the skin. DULLNESS REDNESS Inspired by the princ
Slide 16: 2026 New Launches
2026 NEW LAUNCHES PLANT STEM CELLS PLANT BIOFACTORIES TAILOR-MADE RECOVERY PROCESS ADVANCED RECOVERY PROCESS
Slide 17: ... And More to Come
—— _ AND MORE TO COME to orchestrate regeneration ff esutfdce to depth, resi ‘fullness; resilience and vitality. \ * Krew kind ofdollular intalligence
Slide 18: How We Partner
HOW WE PARTNER Expertise at disposal of our partners to enable long-term value creation and growth EXCLUSIVE Design of “conceptual” complexes of our actives to create tailor made solutions for COMPLEXES our customers. THE POWER Beyond products, technologies that can be customized under request of ou
Slide 19: Custom-Made Development
CUSTOM-MADE DEVELOPMENT 2025-2026
Slide 20: Recoverstem Peptide x New Magic Cream
RECOVERSTEM PEPTIDE X NEW MAGIC CREAM Introducing world-first Recoverstem™ Peptide, backed by 10 years of scientific research. Recoverstem™ Peptide is a blend of over 100 Peptides extracted from the Stem Cells of the Eternal Jasmine Youth Plant™ that never age.
Slide 21: Portfolio of Actives
PORTFOLIO OF ACTIVES Latest Innovation to be always up to time Active Ingredients
Slide 22: Ready for 2027
READY FOR 2027 Set up a distribution network 6 Europe United States 1 Italy United Kingdom Austria France Germany Spain Additional markets to be confirmed
Slide 23: Expanding into Nutraceuticals
EXPANDING INTO NUTRACEUTICALS 01 Discovery platform Applying Arterra’s ingredient discovery platform and scientific expertise to identify new nutraceutical ingredients, including beauty-from-within. 02 Ingredient pipeline Developing promising candidates that address relevant health and wellness targ
Slide 24: Financials
ro) O Cc oO O 6 3.lhC«aS oO 5 (2 = (62 q¢
Slide 25: S1 2026 Financial Highlights
S1 2026 FINANCIAL HIGHLIGHTS VALUE EBITDA NET OF PRODUCTION INCOME € 3,473 € 1,182 € 742 +10.5% 34.0% 21.4% vs S1 2025 MARGIN MARGIN EQUITY NET DEBT (CASH) € (6,094) € 12,347 as of June 30, 2026
Slide 26: S1 Results: 2026 vs 2025 and 2024
S1 RESULTS: 2026 vs 2025 AND 2024 VALUE OF PRODUCTION (/000) EBITDA (/000) NET INCOME (/000) 3.473 3.142 672 34,5% 2.319 37,6% 34,0% 21,4% 22,3% 633 21% 1.085 309 1.181,31 1.181,68 742 3.028 517 2.572 2.251 486,33 -241 -64 -227 S1 2024 S1 2024 S1 2025 S1 2026 S1 2025 S1 2026 Changes in finished p
Slide 27: Annual Results: 2023-2025
ANNUAL RESULTS: 2023-2025 VALUE OF PRODUCTION (€/000) EBITDA (€/000) NET INCOME (€/000) 32,8% 2.500 36,3% 6.115 2.222 25,4% 2.006 4.950 125 21,7% 1.337 5.266 2.000 32,5% 35 1.340 32,1% 1.076 1.712 231 1.058 1.591 1.500 1.416 1.000 4.649 4.173 3.304 500 2023 2024 - 2025 2023 2024 2025 2023 2024 2025
Slide 28: S1 2026 Net Debt and Equity
S1 2026 NET DEBT AND EQUITY NET DEBT (/000) EQUITY (/000) S1 2024 S1 2025 S1 2026 12.347 11.661 10.603 Cash and Cash Equivalents (3.427) (3.442) (1.310) Current Financial Receivables - - - Financial assets other than 891 fixed 1.823 assets (2.472) (2.573) (5.023) Current Financial Debt 43 49 51 Cu
Slide 29: Historical Net Debt and Equity
HISTORICAL NET DEBT AND EQUITY NET DEBT (€/000) EQUITY (€/000) 2023 2024 2025 12.582 Cash and Cash Equivalents (3.686) (3.343) (1.343) 11.423 10.751 Current Financial Receivables - - - Financial assets other than 891 fixed 1.823 assets Current Financial Debt 86 96 93 Current Net Debt (3.599) (3.247)
Slide 30: S1 2026 Growth Drivers
S1 2026 GROWTH DRIVERS REVENUES (/000) 4.000,00 Total value of production increased by 10.5% compared to the 11% 3.472,63 first semester of 2025. 3.500,00 3.142,01 The main driver of this growth was the sale of cosmetic raw 3.000,00 2.687,52 materials, which rose by 22.1% (from 2,200,744 to 22% 2.
Slide 31: Thank You
INVESTOR CONFERENCE NAPLES Banca Profilo THANK YOU
Arterra Bioscience — Investor Conference Naples (Banca Profilo) 2026 on 6ix